AbCellera Biologics, Inc. (ABCL)
11.56
+0.96
(+9.00%)
USD |
NASDAQ |
Aug 25, 09:38
AbCellera Biologics Enterprise Value : 2.822B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.822B |
| August 21, 2026 | 3.040B |
| August 20, 2026 | 3.116B |
| August 19, 2026 | 3.251B |
| August 18, 2026 | 2.978B |
| August 17, 2026 | 3.003B |
| August 14, 2026 | 3.058B |
| August 13, 2026 | 2.932B |
| August 12, 2026 | 2.744B |
| August 11, 2026 | 2.562B |
| August 10, 2026 | 2.433B |
| August 07, 2026 | 1.694B |
| August 06, 2026 | 1.572B |
| August 05, 2026 | 1.385B |
| August 04, 2026 | 1.437B |
| August 03, 2026 | 1.357B |
| July 31, 2026 | 1.320B |
| July 30, 2026 | 1.314B |
| July 29, 2026 | 1.222B |
| July 28, 2026 | 1.192B |
| July 27, 2026 | 1.179B |
| July 24, 2026 | 1.198B |
| July 23, 2026 | 1.308B |
| July 22, 2026 | 1.327B |
| July 21, 2026 | 1.400B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.348B |
| July 17, 2026 | 1.552B |
| July 16, 2026 | 1.458B |
| July 15, 2026 | 1.636B |
| July 14, 2026 | 1.636B |
| July 13, 2026 | 1.569B |
| July 10, 2026 | 1.655B |
| July 09, 2026 | 1.805B |
| July 08, 2026 | 1.746B |
| July 07, 2026 | 1.927B |
| July 06, 2026 | 1.982B |
| July 02, 2026 | 2.056B |
| July 01, 2026 | 1.900B |
| June 30, 2026 | 1.976B |
| June 29, 2026 | 2.078B |
| June 26, 2026 | 1.854B |
| June 25, 2026 | 1.635B |
| June 24, 2026 | 1.443B |
| June 23, 2026 | 1.322B |
| June 22, 2026 | 1.355B |
| June 18, 2026 | 1.291B |
| June 17, 2026 | 1.264B |
| June 16, 2026 | 1.158B |
| June 15, 2026 | 1.209B |
| June 12, 2026 | 1.203B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Jazz Pharmaceuticals Plc | 18.70B |
| Danaher Corp. | 174.72B |
| Illumina, Inc. | 35.07B |
| Bio-Techne Corp. | 11.35B |
| Waters Corp. | 45.26B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.43M |
| Revenue (Quarterly) | 4.05M |
| Total Expenses (Quarterly) | 59.48M |
| EPS Diluted (Quarterly) | -0.1814 |
| Gross Profit Margin (Quarterly) | -116.9% |
| Profit Margin (Quarterly) | -1.37K% |
| Earnings Yield | -4.71% |
| Normalized Earnings Yield | -4.726 |